FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Catalent Indiana FDA-483 Out

[ Price : $8.95]

FDA releases the form FDA-483 with eight observations from a reinspection at the Bloomington, IN-based Catalent Indiana sterile dr...

Amphastar Subsidiary Gets Warning Letter for California Facility

[ Price : $8.95]

FDA sends Amphastar Pharmaceuticals subsidiary International Medication Systems a Warning Letter citing current GMP violations at ...

Operation TrialBlazer May Reshape Clinical Development: Ropes & Gray

[ Price : $8.95]

A Ropes & Gray legal update examines FDA initiatives to shorten drug development timelines and reduce regulatory burdens for spons...

Mixed Stakeholder Views on Priority Voucher Pilot

[ Price : $8.95]

Four stakeholders express varying opinions on the future direction and existence of the FDA national priority drug voucher program...

BlephEx 12-Page Warning Letter

[ Price : $8.95]

FDA warns Brentwood, TN-based BlephEx about multiple violations in its manufacturing of three unapproved ophthalmic devices.

FDA Pauses Release of Complete Response Letters as it Mulls Policy

[ Price : $8.95]

FDA temporarily suspends its controversial practice of publicly releasing Complete Response Letters for rejected drug applications...

J&J Wins Approval for Dual-Energy Cardiac Ablation Platform

[ Price : $8.95]

FDA approves Johnson & Johnsons Dual Energy Thermocool Smarttouch SF Platform, a catheter ablation system that combines pulsed fie...

Restore Former Inspection Processes: Gortler

[ Price : $8.95]

Former FDAer David Gertler says its time for the agency to resume the unannounced, in-person inspections of drug and medical devic...

LyfeUnit Selling Unapproved Ketamine Products: FDA

[ Price : $8.95]

FDA warns that the LyfeUnit Web site is selling unapproved adulterated and misbranded ketamine products.

FDA Moves to Cement Complete Response Letter Transparency Policy

[ Price : $8.95]

FDA looks to formalize one of its most significant transparency initiatives in decades: the public release of Complete Response Le...